These findings suggest that protein methylation of CFLAR by PRMT1 plays a crucial role in the progression of NAFLD, and targeting CFLAR methylation may represent a promising therapeutic strategy for the treatment of NAFLD. Here, CFLAR is linked to metabolic dysfunction-associated steatotic liver disease.